文章基本信息

标题：How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure
本地全文：下载
作者：Jan L Brożek ; Gordon H Guyatt ; Holger J Schünemann 等
期刊名称：Health and Quality of Life Outcomes
印刷版ISSN：1477-7525
电子版ISSN：1477-7525
出版年度：2006
卷号：4
期号：1
页码：69
DOI：10.1186/1477-7525-4-69
语种：English
出版社：BioMed Central
摘要：The evaluation and use of patient reported outcome (PRO) measures requires detailed understanding of the meaning of the outcome of interest. The Food and Drug Administration (FDA) recently presented its draft guidance and view on the use of PRO measures as endpoints in clinical trials. One section of the guidance document specifically deals with advice about the use of the minimal important difference (MID) that we redefined as the smallest difference in score in the outcome of interest that informed patients or informed proxies perceive as important. The advice, however, is short, indeed much too short. We believe that expanding the section and making it more specific will benefit all stakeholders: patients, clinicians, other clinical decision makers, those designing trials and making claims, payers and the FDA. There is no
关键词：Patient Report Outcome ; Item Response Theory ; Minimal Important Difference ; Clinical Trial Result ; Minimal Important Difference Estimate